Carter, K. C. and Henriquez, F. L. and Campbell, S. A. and Roberts, C. W. and Nok, A. and Mullen, A. B. and McFarlane, E. (2007) DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection. Vaccine, 25 (22). pp. 4502-4509. ISSN 0264-410XFull text not available in this repository. (Request a copy from the Strathclyde author)
In this study the potential of using Leishmania donovani gamma-glutamylcysteine synthetase (glutamate-cysteine ligase, gamma-GCS) as a rational target for vaccine development was determined. Mice, immunised with plasmid containing the full gene sequence for gamma-GCS (pVAX-gamma GCS) or plasmid alone (pVAX control), were challenged with a high dose of L. donovani amastigotes to give a stringent test of the ability of the vaccine to protect against infection. Vaccination with pVAX-gamma GCS resulted in the production of specific IgG1 and IgG2a antibodies and resulted in significantly lower liver parasite burdens compared to controls. Protection was also associated with a significant increase in cell-mediated immunity, demonstrated as an increase in nitrite production by ConA stimulated splenocytes, an increase in the percentage of splenic CD3(+)CD4(+) cells, and enhanced granuloma maturation, compared to control values. (C) 2007 Elsevier Ltd. All rights reserved.
|Keywords:||leishmania donovani, gamma-glutamylcysteine synthetase, vaccination, experimental visceral leishmaniasis, sodium stibogluguconate, BALB/C MICE, murine leishmaniasis, toxoplasma-gondii, major infection, in-vivo, responses, susceptibility, resistance, Pharmacy and materia medica, Infectious Diseases, Molecular Medicine, Public Health, Environmental and Occupational Health, veterinary(all), Immunology and Microbiology(all)|
|Subjects:||Medicine > Pharmacy and materia medica|
|Department:||Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences|
|Depositing user:||Pure Administrator|
|Date Deposited:||30 Jun 2011 15:01|
|Last modified:||22 Mar 2017 11:28|